Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Icotinib
Sponsor: Sun Yat-sen University